Probiotics for inflammatory bowel disease: A critical appraisal

Digestive Diseases

Volumn 27, Issue SUPPL. 1, 2010, Pages 111-114

  Sans, Miquel ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Crohn's disease; Inflammatory bowel disease; Probiotics; Ulcerative colitis

Indexed keywords

BETA DEFENSIN; CYTOKINE; LACTOFERRIN; MESALAZINE; PHOSPHOLIPASE; PROBIOTIC AGENT; VSL3;

CONFERENCE PAPER; DRUG EFFICACY; ENTERITIS; EPITHELIUM CELL; HUMAN; ILEITIS; IMMUNOCOMPETENT CELL; INTESTINE ANASTOMOSIS; INTESTINE CELL; INTESTINE FLORA; PREVALENCE; PRIORITY JOURNAL; REMISSION; SACCHAROMYCES BOULARDII; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; METAGENOME; PROBIOTICS;

EID: 77950846694     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268130     Document Type: Conference Paper

References (18)

1. Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
2. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267.
3. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54. (Pubitemid 34049193)
4. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
5. Michail S, Abernathy F: Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli infection. J Pediatr Gastroenterol Nutr 2002; 35: 350-355.
6. Rioux KP, Madsen KL, Fedorak RN: The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol Clin North Am 2005; 34: 465-482, ix. s
7. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebocontrolled trial. Gastroenterology 2000; 119: 305-309
8. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114.
9. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209.
10. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini G, Campieri M: High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50: 2075-2082.
11. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639.
12. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546.
13. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A: Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10:PI126-PI131.
14. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-698.
15. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A: Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574.
16. Isaacs K, Herfarth H: Role of probiotic therapy in IBD. Inflamm Bowel Dis 2008; 14: 1597-1605.
17. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409.
18. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soulé JC, Bourreille A, Metman E, Lerebours E, Carbonnel F, Dupas JL, Veyrac M, Coffin B, Moreau J, Abitbol V, Blum-Sperisen S, Mary JY: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006; 55: 842-847.